Operating Lease, Right-of-Use Asset of Evelo Biosciences, Inc. from 31 Mar 2020 to 30 Sep 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Evelo Biosciences, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2020 to 30 Sep 2023.
  • Evelo Biosciences, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2023 was $0, a 100% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Evelo Biosciences, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $0 -$7,398,000 -100% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $5,765,000 -$2,150,000 -27% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $6,324,000 -$2,095,000 -25% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $6,868,000 -$2,042,000 -23% 31 Dec 2022 10-Q 09 Nov 2023 2023 Q3
Q3 2022 $7,398,000 -$1,991,000 -21% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $7,915,000 -$1,941,000 -20% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $8,419,000 -$1,893,000 -18% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $8,910,000 -$1,847,000 -17% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $9,389,000 -$1,803,000 -16% 30 Sep 2021 10-Q/A 29 Oct 2021 2021 Q3
Q2 2021 $9,856,000 -$1,760,000 -15% 30 Jun 2021 10-Q 29 Jul 2021 2021 Q2
Q1 2021 $10,312,000 -$1,794,000 -15% 31 Mar 2021 10-Q 29 Apr 2021 2021 Q1
Q4 2020 $10,757,000 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $11,192,000 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $11,616,000 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $12,106,000 31 Mar 2020 10-Q 11 May 2020 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.